Últimas noticias sobre Globus Medical (NYSE:GMED) Bolsa

Globus Medical

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.

Globus Medical, Inc. Class A Common Stock

Globus Medical Inc

Lisata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Valo Therapeutics Oy ("ValoTx"), a private company developing novel, adaptable immunotherapies for the treatment of cancer, are pleased to announce a preclinical research collaboration to investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's innovative platform technology, PeptiCRAd, and a checkpoint inhibitor in a melanoma mouse model. Under the agreement, ValoTx will be conducting the research, while Lisata will supply certepetide product.

Biotech

News

General

LSTA

Lisata Therapeutics And Valo Therapeutics Announce Preclinical Research Collaboration To Investigate The Benefits Of Combining Lisata's Novel Product Candidate, Certepetide, With ValoTx's Innovative Platform Technology, PeptiCRAd, And A Checkpoint Inhibitor In A Melanoma Mouse Model

WIIM

RYAM

Rayonier Advanced Materials shares are trading higher. The company reported Q3 financial results.

Hut 8 Corp shares are trading higher after the company announced an initial ASIC fleet upgrade.

CANG

Golden TechGen Expected To Be The Largest Seller In These Transactions, Will Own No More Than 20% Of Cango's Total Outstanding Shares, And All The Sellers In The Share-Settled Transactions Will In The Aggregate Own ~37.8% Of The Co's Total Outstanding Shares

The Scotts Miracle-Gro Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) announced its results Wednesday for the full year and fourth quarter ended Sept. 30, 2024.
"Fiscal 2024 was a strong transition year for the Company in which we continued to transform the business while achieving meaningful top-and bottom-line growth in our core business," said Matt Garth, the company's CFO and chief administrative officer. "We made strategic investments in marketing and innovation to drive sales and support the long-term health of our brands powered by additional efficiency gains across our organization."
Net sales for the company's subsidiary for cannabis growers, Hawthorne Gardening Company, decreased 46% year-over-year to $80.5 million in the fourth quarter of fiscal 2024. The Ohio-based gardening giant reported this trend in <a href="https://www.benzinga.com/markets/cannabis/24/07/40075102/scotts-miracle-gros-cannabis-focused-subsidiary-reports-28-yoy-drop-in-q3-net-sales-reaffirms-20">the previous quarter</a> as well, which it attributed to the previously announced discontinuation of its third-party distributed brands business.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/05/39094250/this-cannabis-merger-will-cover-25-of-u-s-population-cansortium-riv-capital-powered-by-scottsmir">This Cannabis Merger Will Cover 25% Of U.S. Population: Cansortium &amp; RIV Capital Powered By ScottsMiracle-Gro</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Q4 2024 Financial Highlights</h3>
<ul>
<li>Total company net sales were $414.7 million, an increase of 11% from $374.5 million in the same quarter last year.</li>
<li>U.S. consumer net sales increased 54% year-over-year to $309.7 million.</li>
<li>Hawthorne segment sales decreased 46% year-over-year, to $80.5 million.</li>
<li>GAAP and non-GAAP adjusted gross margin rates for the quarter were negative 7.1% and negative 3.1%, respectively, compared to negative 15.2 percent and negative 8.8 percent, respectively, in the prior year's period.</li>
<li>GAAP net loss of $244 million, or $4.29 per share, compared with the prior year's fourth-quarter loss of $468.4 million, or $8.33 per share.</li>
<li>Non-GAAP adjusted net loss for the quarter, which excludes impairment, restructuring and other non-recurring items, was a loss of $131.5 million, or $2.31 per share, compared to a loss of $155.4 million, or $2.77 per share, for the same period last year.</li>
</ul>
<h3 class="wp-block-heading">FY 2024 Financial Highlights</h3>
<ul>
<li>Total net sales were roughly flat compared to the prior year at $3.6 billion.</li>
<li>U.S. Consumer segment sales increased 6% year-over-year, to $3 billion, driven by incremental shelf space, new listings and promotions mainly in the gardens and controls businesses.</li>
<li>Sales for the Hawthorne segment decreased 37% year-over-year to $294.7 million, primarily due to the discontinuation of its third-party distribution business.</li>
<li>The company-wide gross margin rate was 23.9% on a GAAP basis and 26.3% on a non-GAAP adjusted basis compared with rates of 18.5% and 23.7%, respectively, a year ago.</li>
<li>Selling, general and administrative expenses of $559 million were 15.7% of net sales, a 9% decrease from fiscal 2022 reflecting the company's previously announced cost-reduction efforts.</li>
<li>Other operating expenses were $19.9 million primarily due to the discount cost on sales of accounts receivable under the company's accounts receivable sale agreement.</li>
<li>GAAP net loss was $34.9 million, or $0.61 per share, compared with a loss of $380.1 million, or $6.79 per share, in the prior year.</li>
<li>Non-GAAP adjusted EBITDA was $510.1 million for fiscal 2024 including one-time charges of $29 million related to the AeroGarden write-down and other items, compared to $446.9 million last year.</li>
<li>Free cash flow for fiscal 2024 was $583.5 million, compared to $438.2 million a year ago.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39251909/class-action-lawsuit-against-scotts-miracle-gro-investors-allege-misleading-information-and-arti">Class Action Lawsuit Against Scotts Miracle-Gro: Investors Allege &#8216;Misleading Information&#8217; And &#8216;Artificially Inflated Prices&#8217;</a></li>
</ul>
<h3 class="wp-block-heading">SMG Price Action</h3>
The Scotts Miracle-Gro Company's shares traded 4.78% lower at $89 per share during the pre-market session on Wednesday morning.

Cannabis

Earnings

Gardening Giant Scotts Miracle-Gro Reports 46% YoY Drop In Q4 Net Sales For Its Cannabis-Focused Subsidiary

BTBT

Bit Digital shares are trading higher after the company announced growing monthly production updates for October which led to 52.2 BTC produced.

Cango Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) ("Cango" or the "Company"), a leading automotive transaction service platform in China, today announced that it has entered into agreements to purchase on-rack crypto mining machines with an aggregate hashrate of 50 Exahash per second ("EH") for total considerations valued at approximately US$400 million from a group of sellers. The largest seller will be Bitmain Technologies Georgia Limited and Bitmain Development Limited (together, "Bitmain"), a leading manufacturer of digital currency mining servers, and the Company has agreed to purchase from Bitmain on-rack crypto mining machines with an aggregate hashrate of 32EH for a total purchase price of US$256 million in cash (the "Cash-Settled Transaction"). The Company has also agreed to purchase the remaining on-rack crypto mining machines with an aggregate hashrate of 18EH from Golden TechGen Limited ("GT"), a company incorporated under the laws of the British Virgin Islands and wholly owned by Mr. Max HUA ("Mr. Hua"), former chief financial officer of Bitmain and the sole shareholder of GT, and certain other sellers, and will pay the purchase price through issuance of an aggregate of approximately 145,658,192 Class A ordinary shares of the Company (valued at US$144 million) to the sellers in proportion to the aggregate hashrate of the machines to be sold by each seller (the "Share-Settled Transactions", and together with the Cash-Settled Transaction, the "Proposed Transactions").
Upon closing of the Share-Settled Transactions, GT, which is expected to be the largest seller in these transactions, will own no more than 20% of the Company's total outstanding shares, and all the sellers in the Share-Settled Transactions will in the aggregate own approximately 37.8% of the Company's total outstandings shares before any exercise of the warrants described below.&nbsp; The Company also agreed to grant Mr. Hua the right to nominate and appoint two directors of the Company until Mr. Hua and his affiliates cease to hold more than 5% of the Company's total outstanding shares. If the market capitalization of the Company calculated based on the daily volume-weighted average trading price of the Company's ADSs over any consecutive 30-trading days during the 30-month period after closing of the Share-Settled Transactions reaches US$1,825,000,000 (the "Bonus Triggering Event"), the Company agreed to issue at par value approximately 97,105,461 additional Class A ordinary shares to all the sellers in the Share-Settled Transactions as bonus payment in proportion to the aggregate hashrate of the machines to be sold by each seller, and the Company agreed to issue warrants to the sellers that will allow them to exercise such rights within 3 months after the Bonus Triggering Event. &nbsp;Furthermore, if the net asset value (after certain adjustments) of the Company's existing business in China is reduced by RMB50 million or more by the end of 2026 as compared to such value as of September 30, 2024 (the "Adjustment Event"), the Company will be required to issue additional Class A ordinary shares to the Sellers based on the reduced amount. While all the Class A ordinary shares will be issued to the sellers in transactions that are not subject to or exempted from the registration requirement of the U.S. Securities Act of 1933, the Company has granted certain registration rights to the sellers with respect to the shares. The Company will seek shareholders' approval to amend its memorandum and articles of association to increase the Company's total authorized share capital as necessary to effect any share issuance, including under the Bonus Triggering Event or Adjustment Event. As the Company's co-founders, Mr. Xiaojun Zhang and Mr. Jiayuan Lin (the "Co-founders"), will continue to own all the Class B ordinary shares of the Company with super-voting power, the Co-founders are expected to continue to own more than two-thirds of the aggregate voting power of the Company's total outstanding shares (assuming full exercise of the warrants described above) and maintain their control over the Company after completion of the Proposed Transactions.&nbsp;

Cango Enters Into Agreements To Purchase On-Rack Crypto Mining Machines With An Aggregate Hashrate Of 50 EH/s For Total Considerations Valued At ~$400M From A Group Of Sellers

A top mortgage industry executive issued a message to Washington lawmakers this week, calling for immediate action to address <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39614880/now-owning-a-house-in-us-is-more-challenging-than-ever-as-affordability-drops-to-">America&#8217;s mounting housing affordability crisis</a>.
Laura Escobar, newly appointed chair of the Mortgage Bankers Association and president of Lennar Mortgage, told industry leaders at the MBA&#8217;s annual conference in Denver that the American dream of homeownership is slipping away from an increasing number of families.
Don't Miss:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
&#8220;We&#8217;re on the verge of a vicious cycle, in which fewer and fewer people can afford the American dream of homeownership. That&#8217;s not good for America,&#8221; Escobar said Monday, addressing the trade group&#8217;s 275,000 members.
The housing shortage has reached critical levels, with the U.S. facing a deficit of 1.5 million homes, according to Escobar. She pointed to <a href="https://www.benzinga.com/real-estate/24/09/41082529/its-not-a-housing-crisis-but-a-housing-policy-crisis-homebuilders-call-out-roadblocks-as-prices-surg">decades of regulatory barriers that have made it increasingly difficult to construct new homes or renovate existing ones</a>, particularly for smaller builders.
Government regulations add nearly $94,000 to the average price of a new home, according to Market Watch, which cited a 2021 National Association of Home Builders study. Construction costs have risen sharply, with labor and materials expenses jumping 31% since the start of the COVID pandemic.
See Also: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
The impact of the constraints is evident in markets nationwide. In Las Vegas, 34-year-old Andy Balmert spent eight months searching for a home before finally purchasing a two-bedroom condo, made possible only through a $50,000 grant program targeting middle-class buyers.
&#8220;Not as many are wanting to buy houses. But even those who want to simply can&#8217;t without some sort of assistance,&#8221; Justin Jones, a Clark County commissioner, said to Bloomberg.
Restrictive zoning laws compound the problem, with roughly 75% of residential land in the U.S. restricted to single-family homes, Escobar noted. She plans to campaign for loosening regulations in mortgage lending and home building.
The crisis has particularly affected middle-income households. Federal loan data cited by Bloomberg shows that 58% of mid-income households approved for mortgages last year had debt-to-income ratios exceeding 40%, which is the highest level since at least 2018.
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
&#8220;Enough is enough,&#8221; Escobar said. &#8220;My message to every policy maker in Washington D.C. is going to be simple. Stop talking about affordability — and start delivering on affordability.&#8221;
Market conditions remain challenging, with 30-year mortgage rates hovering near 7% and home prices at record levels. According to Fannie Mae, returning to 2016-2019 affordability levels would require either a 38% drop in median home prices, a 60% increase in median household income, or mortgage rates falling to 2.35%.
As the housing crisis moves to the center of national politics, both major presidential candidates have proposed solutions. However, some experts remain skeptical about federal intervention&#8217;s effectiveness.
&#8220;The focus has to be on the supply side,&#8221; Mark Fleming, chief economist at First American Financial Corp, said to Bloomberg. &#8220;The challenge is that there&#8217;s not a lot that the federal government can do. A lot of it is sort of local zoning, local regulatory hurdles.&#8221;
Read Next:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Real Estate

'Stop Talking About Affordability' — Real Estate Exec Calls On Lawmakers To Act On Housing Costs

Qualcomm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) will release earnings results for its fourth quarter, after the <a href="https://www.benzinga.com/quote/qcom/earnings">closing bell on Wednesday, Nov. 6.</a>
Wall Street expects the San Diego, California-based company to report quarterly earnings at $2.56 per share, up from $2.02 per share in the year-ago period. The company projects to report revenue of $9.9 billion, compared to $8.66 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Tuesday, JPMorgan analyst Samik Chatterjee maintained Qualcomm with an Overweight and lowered the price target from $210 to $195.
With the recent buzz around Qualcomm ahead of quarterly earnings, some investors may be eyeing potential gains from the company's dividends, too. Qualcomm currently offers an annual dividend yield of 2.05%. That&#8217;s a quarterly dividend amount of 85 cents per share ($3.40 a year).
To figure out how to earn $500 monthly from Qualcomm, we start with a yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Qualcomm's $3.40 dividend: $6,000 / $3.40 = 1,765 shares.
So, an investor would need to own approximately $292,831 worth of Qualcomm, or 1,765 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $3.40 = 353 shares, or $58,566 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
Price Action: Shares of Qualcomm gained by 0.4% to close at $165.91 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Long Ideas

Markets

QCOM

How To Earn $500 A Month From Qualcomm Stock Ahead Of Q4 Earnings

BTDR

Bitdeer Technologies shares are trading higher after the company announced October 2024 production and operations updates which led to 174 self-mined Bitcoins.

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) with a Buy and lowers the price target from $15 to $14.

Price Target

Analyst Ratings

VERV

HC Wainwright & Co. Maintains Buy on Verve Therapeutics, Lowers Price Target to $14

Neonode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEON#NASDAQ">NEON</a>) reported quarterly losses of $(0.07) per share. This is unchanged from the same period last year. The company reported $800.00 thousand in sales this quarter. This is a 20.24 percent decrease over sales of $1.00 million the same period last year.

NEON

Neonode Q3 EPS $(0.07), Same YoY, Sales $800.00K Down From $1.00M YoY

Barclays analyst Gena Wang maintains CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Equal-Weight and lowers the price target from $59 to $55.

CRSP

Barclays Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $55

Evotec SE shares are trading lower after the company reported worse-than-expected Q3 financial results.

- Launched SEALMINER A2 air and hydro-cooling models with 226 TH/s and 446 TH/s, respectively, and 16.5 J/TH efficiency -&nbsp;Anticipated near-term mass production of approximately 21.7 EH/s of SEALMINER A1 and A2
SINGAPORE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) ("Bitdeer" or the "Company"), a world-leading technology company for blockchain and high-performance computing, today announced its unaudited mining and operations updates for October 2024.
Operational Update
<ul>
<li>Self-mined Bitcoin:&nbsp;174 Bitcoins.</li>
<li>Mining Rig Manufacturing and R&amp;D:
<ul>
<li>SEALMINER A1:
<ul>
<li>Mass production in progress. Approximately 3.7 EH/s of machines to be manufactured and delivered by January 2025, of which approximately 0.4 EH/s of machines are already manufactured and on the way to data centers, and 1.7 EH/s of machines are in production.</li>
<li>On track to be delivered to Texas and Norway sites and fully energized by Q1 2025.</li>
</ul>
</li>
<li>SEALMINER A2:
<ul>
<li>Final testing of air and hydro-cooling mining machines achieved 226 TH/s and 446 TH/s, respectively and 16.5 J/TH efficiency.</li>
<li>Commenced mass production. Secured capacity as of this report date will generate approximately 18 EH/s hashrate, expected to be used for sale to external customers and self-mining.</li>
</ul>
</li>
<li>SEAL03:
<ul>
<li>Successfully taped-out SEAL03 chip in October with an expected chip efficiency of 10 J/TH.</li>
</ul>
</li>
</ul>
</li>
<li>HPC/AI:
<ul>
<li>TLM Group successfully completed its feasibility assessment of Bitdeer's U.S. sites, reporting positive results regarding suitability for Tier 3 HPC/AI datacenters, due to the availability of land, power, fiber and water resources.</li>
<li>Discussions ongoing with multiple development partners and potential end users for these sites.</li>
<li>Bitdeer AI cloud services powered by NVIDIA DGX SuperPod with H100 systems achieved approximately 90% average utilization.</li>
</ul>
</li>
<li>Hosting:
<ul>
<li>Client-hosted mining machines increased by 3,000 units, contributing approximately 0.8 EH/s.</li>
</ul>
</li>
<li>Mining Datacenters:
<ul>
<li>Construction of the Tydal, Norway, 40 MW phase 1 expansion remains on track to be energized in December 2024.</li>
<li>Rockdale, Texas, USA, 100MW hydro-cooling conversion expected to be delayed one month from original schedule due to the US dock workers strike in early October. Expected phased completion during Q1 2025.</li>
<li>Jigmeling, Bhutan, 500 MW construction remains on track with the primary substation expected to be completed by Q1 2025.</li>
</ul>
</li>
</ul>

Bitdeer Announces October 2024 Production And Operations Update; Self-Mined 174 Bitcoins; Anticipating Near-Term Mass Production Of ~21.7 EH/s Of SEALMINER A1 And A2

Barclays analyst Michael Leithead maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Equal-Weight and lowers the price target from $151 to $101.

Barclays Maintains Equal-Weight on Celanese, Lowers Price Target to $101

Barclays analyst Terence Malone maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $75 to $69.

BRKR

Barclays Maintains Overweight on Bruker, Lowers Price Target to $69

Vishay Intertechology shares are trading lower after the company reported worse-than-expected Q3 financial results and issued Q4 revenue guidance below estimates. Also, the company announced the acquisition of Birkelbach for $18.5 million

Barclays analyst Lauren Lieberman maintains BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) with a Overweight and raises the price target from $68 to $74.

BRBR

Barclays Maintains Overweight on BellRing Brands, Raises Price Target to $74

Keybanc analyst Weston Twigg maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Overweight and lowers the price target from $100 to $95.

MCHP

Keybanc Maintains Overweight on Microchip Technology, Lowers Price Target to $95

Globus Medical ( ($GMED) ) has released its Q3 earnings. Here is a breakdown of the information Globus Medical presented to its investors. Globus M...

Globus Medical Reports Robust Q3 2024 Financial Growth

BTIG analyst Ryan Zimmerman maintained a Buy rating on Globus Medical (GMED – Research Report) today and set a price target of $87.00. The company'...

BTIG Sticks to Its Buy Rating for Globus Medical (GMED)

Wells Fargo analyst Vik Chopra raised the firm's price target on Globus Medical (GMED) to $88 from $78 and keeps an Overweight rating on the shares...

Globus Medical price target raised to $88 from $78 at Wells Fargo

Wells Fargo analyst Vik Chopra has assigned their bullish stance on GMED stock, giving a Buy rating yesterday. Vik Chopra has given his Buy rating ...

Globus Medical's Strong Q3 Performance and Optimistic Outlook Justify Buy Rating

Truist Financial analyst Richard Newitter maintained a Hold rating on Globus Medical (GMED – Research Report) today and set a price target of $85.0...

Truist Financial Sticks to Its Hold Rating for Globus Medical (GMED)

Piper Sandler Reaffirms Their Buy Rating on Globus Medical (GMED)

Piper Sandler analyst Matt O'Brien raised the firm's price target on Globus Medical (GMED) to $100 from $80 and keeps an Overweight rating on the s...

Globus Medical price target raised to $100 from $80 at Piper Sandler

Stifel analyst Mathew Blackman raised the firm's price target on Globus Medical (GMED) to $92 from $80 and keeps a Buy rating on the shares. Q3 "se...

Globus Medical price target raised to $92 from $80 at Stifel

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – CVS Health (CVS) up 12% Vertex (VERX) up 6% I...

Morning Movers: CVS Health surges and ODP sinks following Q3 results

RBC Capital raised the firm's price target on Globus Medical (GMED) to $92 from $80 and keeps an Outperform rating on the shares. The company issue...

Globus Medical price target raised to $92 from $80 at RBC Capital

ATHM

AUDC

CELH

ENOV

EXAS

GMED

HNDAF

IONS

IRBT

VERX

Legal

Press Releases

Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Customers Bancorp, Globus, and Domino's and Encourages Investors to Contact the Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED

GMED Investors Have Opportunity to Join Globus Medical, Inc. Securities Fraud Investigation with the Schall Law Firm

Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Customers Bancorp, Globus, and Metagenomi and Encourages Investors to Contact the Firm

Globus Medical Launches the Next Wave of Orthopedic Trauma Solutions

Globus Medical Schedules Third Quarter Earnings Release and Conference Call

Health Care

Globus Medical to Participate in Orthopedic Trauma Association Annual Meeting

Globus Medical Reports Third Quarter 2024 Results

CUBI

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Piper Sandler

B of A Securities

BTIG

RBC Capital

Barclays

Globus Medical shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 guidance above estimates.

Comments

Globus Medical

Noticias

Últimas noticias sobre Globus Medical (NYSE:GMED) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL